Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component

Lung Cancer

Volumn 72, Issue 3, 2011, Pages 309-315

  Yoshida, Akihiko ^a,b   Tsuta, Koji ^a   Watanabe, Shun ichi ^a   Sekine, Ikuo ^a   Fukayama, Masashi ^b   Tsuda, Hitoshi ^a   Furuta, Koh ^a   Shibata, Tatsuhiro ^c  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Adenocarcinoma; ALK translocation; Fluorescence in situ hybridization; Immunohistochemistry; Polymerase chain reaction; Signet ring cell

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P63; THYROID TRANSCRIPTION FACTOR 1;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GROWTH; CELL ADHESION; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOARCHITECTURE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE EXPRESSION; GENE FUSION; GENE MUTATION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MALE; ONCOGENE K RAS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNET RING CARCINOMA;

ADULT; AGED; CARCINOMA, SIGNET RING CELL; CELL CYCLE PROTEINS; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; RECEPTOR PROTEIN-TYROSINE KINASES; SERINE ENDOPEPTIDASES;

EID: 79955467025     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.09.013     Document Type: Article

References (37)

1. Travis W.D., Brambilla E., Muller-Hermelink H.K., Harris C.C. Pathology and genetics: tumours of the lung, pleura, thymus and heart 2004, IARC Press, Lyon, France.
2. Horn L., Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol 2009, 27:4232-4235.
3. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
4. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
5. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
6. Boland J.M., Erdogan S., Vasmatzis G., Yang P., Tillmans L.S., Erickson Johnson M.R., et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol 2009, 40:1152-1158.
7. Choi Y.L., Takeuchi K., Soda M., Inamura K., Togashi Y., Hatano S., et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 2008, 68:4971-4976.
8. Inamura K., Takeuchi K., Togashi Y., Hatano S., Ninomiya H., Motoi N., et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009, 22:508-515.
9. Inamura K., Takeuchi K., Togashi Y., Nomura K., Ninomiya H., Okui M., et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008, 3:13-17.
10. Koivunen J.P., Mermel C., Zejnullahu K., Murphy C., Lifshits E., Holmes A.J., et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008, 14:4275-4283.
11. Rodig S.J., Mino-Kenudson M., Dacic S., Yeap B.Y., Shaw A., Barletta J.A., et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009, 15:5216-5223.
12. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27:4247-4253.
13. Shinmura K., Kageyama S., Tao H., Bunai T., Suzuki M., Kamo T., et al. EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer 2008, 61:163-169.
14. Takahashi T., Sonobe M., Kobayashi M., Yoshizawa A., Menju T., Nakayama E., et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 2010, 17:889-897.
15. Takeuchi K., Choi Y.L., Togashi Y., Soda M., Hatano S., Inamura K., et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009, 15:3143-3149.
16. Wong D.W., Leung E.L., So K.K., Tam I.Y., Sihoe A.D., Cheng L., et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009, 115:1723-1733.
17. Solomon B., Varella-Garcia M., Camidge D.R. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 2009, 4:1450-1454.
18. Soda M., Takada S., Takeuchi K., Choi Y.L., Enomoto M., Ueno T., et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA 2008, 105:19893-19897.
19. Kwak E.L., Camidge D.R. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341966. J Clin Oncol 2009, 27.
20. Kish J.K., Ro J.Y., Ayala A.G., McMurtrey M.J. Primary mucinous adenocarcinoma of the lung with signet-ring cells: a histochemical comparison with signet-ring cell carcinomas of other sites. Hum Pathol 1989, 20:1097-1102.
21. Tsuta K., Ishii G., Yoh K., Nitadori J., Hasebe T., Nishiwaki Y., et al. Primary lung carcinoma with signet-ring cell carcinoma components: clinicopathological analysis of 39 cases. Am J Surg Pathol 2004, 28:868-874.
22. Ou S.H., Ziogas A., Zell J.A. Primary signet-ring carcinoma (SRC) of the lung: a population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung. J Thorac Oncol 2010, 5:420-427.
23. Castro C.Y., Moran C.A., Flieder D.G., Suster S. Primary signet ring cell adenocarcinomas of the lung: a clinicopathological study of 15 cases. Histopathology 2001, 39:397-401.
24. Hayashi H., Kitamura H., Nakatani Y., Inayama Y., Ito T., Kitamura H. Primary signet-ring cell carcinoma of the lung: histochemical and immunohistochemical characterization. Hum Pathol 1999, 30:378-383.
25. Merchant S.H., Amin M.B., Tamboli P., Ro J., Ordonez N.G., Ayala A.G., et al. Primary signet-ring cell carcinoma of lung: immunohistochemical study and comparison with non-pulmonary signet-ring cell carcinomas. Am J Surg Pathol 2001, 25:1515-1519.
26. Maeshima A., Miyagi A., Hirai T., Nakajima T. Mucin-producing adenocarcinoma of the lung, with special reference to goblet cell type adenocarcinoma: immunohistochemical observation and Ki-ras gene mutation. Pathol Int 1997, 47:454-460.
27. Iwasaki T., Ohta M., Lefor A.T., Kawahara K. Signet-ring cell carcinoma component in primary lung adenocarcinoma: potential prognostic factor. Histopathology 2008, 52:639-640.
28. Tsuta K., Ishii G., Nitadori J., Murata Y., Kodama T., Nagai K., et al. Comparison of the immunophenotypes of signet-ring cell carcinoma, solid adenocarcinoma with mucin production, and mucinous bronchioloalveolar carcinoma of the lung characterized by the presence of cytoplasmic mucin. J Pathol 2006, 209:78-87.
29. International Union Against Cancer (UICC) TNM classification of malignant tumours 2002, Wiley-Liss, New York. 6th ed. L.H. Sobin, C. Wittekind (Eds.).
30. Paik J., Choe J., Chung J. Protein expression and gene rearrangement of ALK in non-small cell lung carcinomas. Mod Pathol 2010, 23:411A.
31. Fukui T., Ohe Y., Tsuta K., Furuta K., Sakamoto H., Takano T., et al. Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer. Clin Cancer Res 2008, 14:4751-4757.
32. Sakuma Y., Matsukuma S., Yoshihara M., Nakamura Y., Noda K., Nakayama H., et al. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. Am J Clin Pathol 2007, 128:100-108.
33. Sarma D.P., Hoffmann E.O. Primary signet-ring cell carcinoma of the lung. Hum Pathol 1990, 21:459-460.
34. Sheikh H.A., Fuhrer K., Cieply K., Yousem S. p63 expression in assessment of bronchioloalveolar proliferation of the lung. Mod Pathol 2004, 17:1134-1140.
35. Wu M., Orta L., Gil J., Li G., Hu A., Burstein D.E. Immunohistochemical detection of XIAP and p63 in adenomatous hyperplasia, atypical adenomatous hyperplasia, bronchioloalveolar carcinoma and well-differentiated adenocarcinoma. Mod Pathol 2008, 21:553-558.
36. Ang D., Ghaffar H., Zakowski M., Teruya-Feldstein J., Moreira A., Rekhtman N. Expression of squamous markers in lung adenocarcinoma: clinicopathologic and molecular correlates, and implications for differentiation from squamous cell carcinoma. Mod Pathol 2010, 23:397A.
37. Nakayama T., Miyabe S., Okabe M., Sakuma H., Ijichi K., Hasegawa Y., et al. Clinicopathological significance of the CRTC3-MAML2 fusion transcript in mucoepidermoid carcinoma. Mod Pathol 2009, 22:1575-1581.